The clinical data verified the association of the identified genes (i.e., KIF2C, CCNA2, NDC80, KIF11, KIF23, ANLN, and CENPM) with the targeted therapy response and prognosis of glioma patients (Fig 5). This evidence concerns the gene CCNA2 and central nervous system cancer.